AbbVie's etentamig succeeds in Phase 3 myeloma trial, cutting progression risk by 60%

AbbVie reported that its investigational T cell engager etentamig reduced the risk of disease progression or death by 60% versus standard care in a late-stage multiple myeloma study. The company plans to move forward with regulatory submissions based on these results.

Multiple myeloma is a complex blood cancer that often relapses, creating ongoing demand for new treatment strategies. T cell engagers are an emerging immunotherapy class designed to harness the immune system more directly against malignant cells.

Etentamig's reported 60% reduction in progression or death risk versus standard care in a Phase 3 trial positions it as a potentially significant option. AbbVie's intent to file regulatory submissions reflects confidence in the data, though full results and safety details remain pending.